This article is more than 5 years old. Information may no longer be current.

Solutis SLT system cleared for clinical use

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Food and Drug Administration has cleared Quantel Medical’s Solutis selective laser trabeculoplasty system for clinical use, according to a news release.

SLT is designed to function as a first-line or adjunct therapy to noninvasively reduce IOP in primary open-angle glaucoma patients via targeted laser energy.

Quantel has marketed the device outside the United States since 2007, but had been restricted from marketing within the United States due to a patent held by Massachusetts General Hospital that has since expired.